Fresenius Kabi Slade sale
July 27, 2015
Freseni us Kabi has announced
the sale of its oncology
compounding business in Australia,
with pharmacy group Slade Health
to take over the company’s TGA
licenced facilities in Queensland,
NSW and Victoria.
The deal will also see Slade
become the exclusive supplier of
compounded parenteral nutrition
products to Fresenius Kabi Australia.
While David and Graham Slade
will continue to independently
own and operate all existing Slade
Pharmacy businesses after the deal
is settled, Slade Health is also set to
join the Icon Consolidated Holdings
group of companies, in a broader
arrangement that will “bring
together the procurement and back
of house activities supporting Icon
Cancer Care, Epic Pharmacies and
the Slade Group.
Slade md David Slade said the
Fresenius Kabi acquisition boosts
the company’s presence in the
sterile TGA compounding market
across Australia’s east coast.
“Fresenius Kabi has built a
fantastic business across Australia,
with great people, facilities and
significant customer relationships.
“The acquisition will expand
our product range and bring our
compounding services closer to our
customers in NSW and Queensland
to ensure the continued supply of
critical medications,” he said.
Slade intends to retain the
staff currently employed at the
Fresenius Kabi facilities.
Fresenius Kabi said it remains
strongly committed to Australia,
and will focus on its core product
areas of infusion solutions, IV
drugs, clinical nutrition and medical
devices.
“Fresenius Kabi will continue to
be a reliable and trusted partner for
medicines to help care for critically
and chronically ill patients and will
continue to provide high quality
products to Australian hospitals and
healthcare facilities,” said Fresenius
Kabi country manager Australia/NZ,
Juan Villar.
The above article was sent to subscribers in Pharmacy Daily's issue from 27 Jul 15To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 27 Jul 15
